Botanix Pharmaceuticals Limited (BXPHF)
USD 0.23
(0.0%)
USD 0.23
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | -79.3 Million AUD | -673.71% |
| 2023 | -10.25 Million AUD | -43.1% |
| 2022 | -7.16 Million AUD | 66.36% |
| 2021 | -21.29 Million AUD | 12.09% |
| 2020 | -24.22 Million AUD | -414.93% |
| 2019 | -4.7 Million AUD | 72.75% |
| 2018 | -17.26 Million AUD | -201.78% |
| 2017 | -5.72 Million AUD | -56.64% |
| 2016 | -3.65 Million AUD | -179.05% |
| 2015 | -1.3 Million AUD | 47.91% |
| 2014 | -2.51 Million AUD | -688.83% |
| 2013 | 426.71 Thousand AUD | -8.62% |
| 2012 | 466.95 Thousand AUD | 53.8% |
| 2011 | 303.61 Thousand AUD | 1014.22% |
| 2010 | -33.21 Thousand AUD | -243.72% |
| 2009 | -9662.00 AUD | 97.41% |
| 2008 | -373.07 Thousand AUD | 74.77% |
| 2007 | -1.47 Million AUD | -188.91% |
| 2006 | -511.79 Thousand AUD | 69.49% |
| 2005 | -1.67 Million AUD | -28.35% |
| 2004 | -1.3 Million AUD | -48.86% |
| 2003 | -878 Thousand AUD | 70.38% |
| 2002 | -2.96 Million AUD | 49.12% |
| 2001 | -5.82 Million AUD | -32.71% |
| 2000 | -4.39 Million AUD | -576.43% |
| 1999 | -649 Thousand AUD | 84.47% |
| 1998 | -4.18 Million AUD | -321.37% |
| 1997 | -992 Thousand AUD | 65.77% |
| 1996 | -2.89 Million AUD | -229.69% |
| 1995 | -879 Thousand AUD | -131.37% |
| 1994 | 2.8 Million AUD | -34.21% |
| 1993 | 4.25 Million AUD | -24.12% |
| 1992 | 5.61 Million AUD | 11.92% |
| 1991 | 5.01 Million AUD | -7.15% |
| 1990 | 5.4 Million AUD | 5.04% |
| 1989 | 5.14 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -18.31 Million AUD | 0.0% |
| 2024 Q4 | -79.3 Million AUD | 0.0% |
| 2024 FY | -79.3 Million AUD | -673.71% |
| 2024 Q3 | -79.3 Million AUD | -333.06% |
| 2024 Q1 | -18.31 Million AUD | -155.66% |
| 2023 Q1 | -8.71 Million AUD | -21.67% |
| 2023 Q4 | -7.16 Million AUD | 30.12% |
| 2023 Q3 | -10.25 Million AUD | -18.05% |
| 2023 FY | -10.25 Million AUD | -43.1% |
| 2023 Q2 | -8.68 Million AUD | 0.37% |
| 2022 Q1 | -16.82 Million AUD | 20.99% |
| 2022 Q4 | -7.16 Million AUD | 1.68% |
| 2022 Q3 | -7.28 Million AUD | 56.24% |
| 2022 Q2 | -16.65 Million AUD | 1.04% |
| 2022 FY | -7.16 Million AUD | 66.36% |
| 2021 Q3 | -21.44 Million AUD | -13.43% |
| 2021 Q4 | -21.29 Million AUD | 0.69% |
| 2021 Q1 | -19.02 Million AUD | 21.47% |
| 2021 Q2 | -18.9 Million AUD | 0.62% |
| 2021 FY | -21.29 Million AUD | 12.09% |
| 2020 Q3 | -24.34 Million AUD | 8.88% |
| 2020 Q1 | -26.81 Million AUD | -470.01% |
| 2020 FY | -24.22 Million AUD | -414.93% |
| 2020 Q4 | -24.22 Million AUD | 0.51% |
| 2020 Q2 | -26.72 Million AUD | 0.35% |
| 2019 Q4 | -4.7 Million AUD | 0.0% |
| 2019 FY | -4.7 Million AUD | 72.75% |
| 2019 Q1 | -13.53 Million AUD | 21.62% |
| 2019 Q2 | -13.53 Million AUD | 0.0% |
| 2019 Q3 | -4.7 Million AUD | 65.23% |
| 2018 Q2 | -2.24 Million AUD | 0.0% |
| 2018 Q3 | -17.26 Million AUD | -668.64% |
| 2018 Q4 | -17.26 Million AUD | 0.0% |
| 2018 FY | -17.26 Million AUD | -201.78% |
| 2018 Q1 | -2.24 Million AUD | 60.74% |
| 2017 Q4 | -5.72 Million AUD | 0.0% |
| 2017 Q3 | -5.72 Million AUD | -141.21% |
| 2017 FY | -5.72 Million AUD | -56.64% |
| 2017 Q1 | -2.37 Million AUD | 35.06% |
| 2017 Q2 | -2.37 Million AUD | 0.0% |
| 2016 FY | -3.65 Million AUD | -179.05% |
| 2016 Q4 | -3.65 Million AUD | 0.0% |
| 2015 FY | -1.3 Million AUD | 47.91% |
| 2015 Q4 | -1.3 Million AUD | 0.0% |
| 2014 Q4 | -2.51 Million AUD | 0.0% |
| 2014 FY | -2.51 Million AUD | -688.83% |
| 2013 FY | 426.71 Thousand AUD | -8.62% |
| 2013 Q4 | 426.71 Thousand AUD | 0.0% |
| 2012 Q4 | 466.95 Thousand AUD | 0.0% |
| 2012 FY | 466.95 Thousand AUD | 53.8% |
| 2011 FY | 303.61 Thousand AUD | 1014.22% |
| 2011 Q4 | 50.65 Thousand AUD | 0.0% |
| 2010 FY | -33.21 Thousand AUD | -243.72% |
| 2010 Q4 | -33.21 Thousand AUD | 0.0% |
| 2009 Q4 | -9662.00 AUD | 0.0% |
| 2009 FY | -9662.00 AUD | 97.41% |
| 2008 FY | -373.07 Thousand AUD | 74.77% |
| 2008 Q4 | -373.07 Thousand AUD | 0.0% |
| 2007 Q4 | -1.47 Million AUD | 0.0% |
| 2007 FY | -1.47 Million AUD | -188.91% |
| 2006 Q4 | -220.55 Thousand AUD | 0.0% |
| 2006 FY | -511.79 Thousand AUD | 69.49% |
| 2005 FY | -1.67 Million AUD | -28.35% |
| 2005 Q4 | -1.67 Million AUD | 0.0% |
| 2004 Q4 | -1.3 Million AUD | 0.0% |
| 2004 FY | -1.3 Million AUD | -48.86% |
| 2003 FY | -878 Thousand AUD | 70.38% |
| 2003 Q4 | -878.01 Thousand AUD | 0.0% |
| 2002 Q4 | -2.96 Million AUD | 0.0% |
| 2002 FY | -2.96 Million AUD | 49.12% |
| 2001 Q4 | -5.82 Million AUD | 0.0% |
| 2001 FY | -5.82 Million AUD | -32.71% |
| 2000 Q4 | -4.39 Million AUD | 0.0% |
| 2000 FY | -4.39 Million AUD | -576.43% |
| 1999 Q4 | -649 Thousand AUD | 0.0% |
| 1999 FY | -649 Thousand AUD | 84.47% |
| 1998 FY | -4.18 Million AUD | -321.37% |
| 1997 FY | -992 Thousand AUD | 65.77% |
| 1997 Q4 | -3.07 Million AUD | 0.0% |
| 1996 FY | -2.89 Million AUD | -229.69% |
| 1995 FY | -879 Thousand AUD | -131.37% |
| 1994 FY | 2.8 Million AUD | -34.21% |
| 1993 FY | 4.25 Million AUD | -24.12% |
| 1992 FY | 5.61 Million AUD | 11.92% |
| 1991 FY | 5.01 Million AUD | -7.15% |
| 1990 FY | 5.4 Million AUD | 5.04% |
| 1989 FY | 5.14 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ContraFect Corporation | -6.02 Million USD | -1216.099% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 603.128% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 2025.878% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 19835.804% |
| SQZ Biotechnologies Company | -36.23 Million USD | -118.853% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 3637.016% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 285.33% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -1157.956% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 8653.638% |
| Marizyme, Inc. | 18.56 Million USD | 527.099% |
| Genus plc | 190.6 Million USD | 141.61% |
| Pharming Group N.V. | 109.8 Million USD | 172.227% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 9319.292% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 6633.398% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 11762.96% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 6963.955% |
| IMV Inc. | 7.67 Million USD | 1133.934% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 1541.469% |
| ONE Bio Corp. | 9.04 Million USD | 977.299% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 712.607% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 12843.046% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 7970.087% |
| Biomind Labs Inc. | 711.4 Thousand USD | 11248.145% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 230.989% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 719.276% |
| Skye Bioscience, Inc. | -5.72 Million USD | -1286.169% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 22147.797% |
| Mesoblast Limited | 55.85 Million USD | 241.981% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 56828.084% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 1504.089% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 399295.299% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 3701.672% |
| GB Sciences, Inc. | 1.74 Million USD | 4638.854% |
| MultiCell Technologies, Inc. | 90.04 USD | 88081097.335% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -43051.963% |
| HST Global, Inc. | 96.79 Thousand USD | 82035.811% |
| CSL Limited | 10.52 Billion USD | 100.753% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Agentix Corp. | 37.63 Thousand USD | 210852.119% |
| Halberd Corporation | 144.72 Thousand USD | 54900.706% |
| Enzolytics Inc. | 981.65 Thousand USD | 8179.014% |
| Resverlogix Corp. | 6.45 Million USD | 1329.393% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -11682.711% |
| argenx SE | -2.02 Billion USD | 96.091% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | -68.698% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 359.567% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -797.16% |
| Bioxytran, Inc. | 1.89 Million USD | 4276.499% |
| Zenith Capital Corp. | 10.06 Thousand USD | 788137.858% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 3423.847% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 48308.992% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -432851.905% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Adynxx, Inc. | - USD | Infinity% |
| Genscript Biotech Corporation | -1.06 Billion USD | 92.528% |
| Kadimastem Ltd | -253.1 Thousand USD | -31234.454% |
| Helix BioMedix, Inc. | -2.57 Million USD | -2985.881% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 4066.612% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 491.143% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 3647.142% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 59004.277% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -10705.246% |
| EV Biologics, Inc. | 1.36 Million USD | 5897.501% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 39506.983% |
| Q BioMed Inc. | 4.06 Million USD | 2053.398% |
| LadRx Corporation | -2.03 Million USD | -3794.394% |
| Cell Source, Inc. | 9.23 Million USD | 959.06% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -388512.946% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 12586.186% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 282.595% |
| Itoco Inc. | 228.3 Thousand USD | 34837.798% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 58419.518% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 38558.58% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 1221.602% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 1699.922% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 3027.996% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -5.9 Million USD | -1243.475% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 39668.597% |
| NovAccess Global Inc. | 2.17 Million USD | 3740.551% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -12257725.348% |
| BioStem Technologies, Inc. | 4.47 Million USD | 1873.433% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -855588.613% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -6053955.725% |
| Qrons Inc. | 351.42 Thousand USD | 22667.455% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 1129.173% |
| SYBLEU INC | 473.71 Thousand USD | 16841.775% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -31671.545% |
| Rebus Holdings, Inc. | 305 Thousand USD | 26102.666% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 12586.186% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 1879.397% |
| Affymax, Inc. | -5.59 Million USD | -1316.976% |
| Mobile Lads Corp. | 484.23 Thousand USD | 16478.127% |
| International Stem Cell Corporation | 2.59 Million USD | 3162.09% |
| CytoDyn Inc. | 20.26 Million USD | 491.413% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 127169.889% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 3736.486% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 2409.497% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 1027.255% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 10365.003% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -6244.65% |
| Neutra Corp. | 52.18 Thousand USD | 152069.13% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -3086.345% |
| PureTech Health plc | -167.19 Million USD | 52.566% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -32282.825% |
| IXICO plc | -4.44 Million USD | -1684.376% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 699.956% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 244.588% |
| CSL Limited | 10.52 Billion USD | 100.753% |
| Cellectis S.A. | -43.81 Million USD | -80.991% |